Mutaz Fahad Felemban¹, Azizah Fahad Bin Mubayrik²* and Hael Hani Mukhtar³

¹Graduate Student, Doctor of Science in Dentistry Oral Medicine Track, College of Dentistry, King Saud University, Saudi Arabia
²Division of Oral Medicine, Department of Oral medicine and Diagnostic Sciences, College of Dentistry, King Saud University, Saudi Arabia
³Graduate student, Doctor of Science in Dentistry Oral Medicine Track, College of Dentistry, King Saud University, Saudi Arabia

*Corresponding Author: Azizah Fahad Bin Mubayrik, Division of Oral Medicine, Department of Oral medicine and Diagnostic Sciences, College of Dentistry, King Saud University, Saudi Arabia.

Received: December 04, 2023; Published: December 20, 2023

Abstract

Tumor cells can evade and suppress immune response through various mechanisms such as T cell activation suppression by PD-1 and/or CTLA-4. The main objective of this study is to examine the checkpoint inhibitors immunotherapy for head and neck cancer. Data were collected in numerous areas from various medical databases. The data collected and were thoroughly analyzed. Major findings of the studies were analyzed and presented in this article. Conclusions: The findings showed that immunotherapy is promising to increase survival rate and control of metastasis.

Keywords:Cancer Immunotherapy; Immune Checkpoint Inhibitors; Head and Neck Cancer; Monoclonal Antibodies Therapy; Cytokines Immunothearpy

References

1. Mandal R., et al. “The head and neck cancer immune landscape and its immunotherapeutic implications”. JCI Insight17 (2016).
2. Almangush A., et al. “Prognostic biomarkers for oral tongue squamous cell carcinoma: A systematic review and meta-analysis”. British Journal of Cancer 6 (2016).
3. Rivera C., et al. “Prognostic biomarkers in oral squamous cell carcinoma: A systematic review”. Oral Oncology 2 (2017).
4. Nandini DB., et al. “Novel therapies in the management of oral cancer: An update”. Disease-a-Month 66 (2020).
5. Tan S., et al. “Cancer immunotherapy: Pros, cons and beyond”. Biomedicine and Pharmacotherapy 124 (2020).
6. McCarthy EF. “The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas”. Iowa Orthopedic Journal (2006): 26.
7. Hanahan D and Weinberg RA. “Hallmarks of cancer: The next generation”. Cell 144 (2011).
8. Beatty GL and Gladney WL. “Immune escape mechanisms as a guide for cancer immunotherapy”. Clinical Cancer Research 21 (2015).
9. Whiteside TL. “Immunobiology of head and neck cancer”. Cancer and Metastasis Reviews 24 (2005).
10. Lee L., et al. “Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy”. Journal of Clinical Pharmacology 56 (2016).
11. Weiner LM., et al. “Monoclonal antibodies for cancer immunotherapy”. The Lancet 373 (2009).
12. Kimiz-Gebologlu I., et al. “Monoclonal antibodies in cancer immunotherapy”. Molecular Biology Reports 45 (2018).
13. Tojjari A., et al. “A Comprehensive Review on Cancer Vaccines and Vaccine Strategies in Hepatocellular Carcinoma”. Vaccines 11 (2023).
14. Lee S and Margolin K. “Cytokines in cancer immunotherapy”. Cancers 3 (2011).
15. Akhoundi M., et al. “CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities”. Cellular Oncology 44 (2021).
16. Huang PW and Chang JWC. “Immune checkpoint inhibitors win the 2018 Nobel Prize”. Biomedical Journal 42 (2019).
17. Zitvogel L and Kroemer G. “Targeting PD-1/PD-L1 interactions for cancer immunotherapy”. OncoImmunology 1 (2012).
18. Yi JS., et al. “T-cell exhaustion: Characteristics, causes and conversion”. Immunology 129 (2010).
19. Jie HB., et al. “Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients”. British Journal of Cancer 10 (2013).
20. Tie Y., et al. “Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets”. Journal of Hematology and Oncology 15 (2022).
21. Whiteside TL. “Immunobiology of head and neck cancer”. Cancer Metastasis Review1 (2005): 95-105.
22. Strauss L., et al. “The frequency and suppressor function of CD4+CD25 highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck”. Clinical Cancer Research21 (2007): 6301-6311.
23. Zandberg DP and Strome SE. “The role of the PD-L1: PD-1 pathway in squamous cell carcinoma of the head and neck”. Oral Oncology 50 (2014).
24. Schoenfeld JD., et al. “Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial”. JAMA Oncology 10 (2020).
25. Tímár J., et al. “Molecular pathology of tumor metastasis III. Target array and combinatorial therapies”. In: Pathology and Oncology Research (2003).
26. Whiteside TL. “Immunobiology and immunotherapy of head and neck cancer”. Current Oncology Reports 3 (2001).
27. Yokota T., et al. “Immunotherapy for squamous cell carcinoma of the head and neck”. Japanese Journal of Clinical Oncology 50 (2020).
28. Sklan A and Collingridge D. “Treating head and neck cancer: for better or for worse?” The Lancet Oncology 18 (2017).
29. Vermorken JB., et al. “Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer”. New England Journal of Medicine11 (2008).
30. Kao HF and Lou PJ. “Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions”. In: Head and Neck (2019).
31. Siu LL., et al. “Safety and Efficacy of Durvalumab with or Without Tremelimumab in Patients with PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial”. JAMA Oncology2 (2019).
32. Burtness B., et al. “Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study”. The Lancet10212 (2019).
33. Bonner JA., et al. “Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival”. Lancet Oncology1 (2010).
34. Gillison ML., et al. “Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial”. The Lancet10166 (2019).
35. Mehanna H., et al. “Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial”. The Lancet 10166 (2019).
36. Twyman-Saint Victor C., et al. “Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer”. Nature 7547 (2015).
37. Sridharan V., et al. “Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer”. British Journal of Cancer 2 (2016).
38. Wolchok JD., et al. “Nivolumab plus Ipilimumab in Advanced Melanoma”. New England Journal of Medicine2 (2013).
39. Gandhi L., et al. “Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer”. New England Journal of Medicine22 (2018).
40. Socinski MA., et al. “Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC”. New England Journal of Medicine24 (2018).
41. Horn L., et al. “First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer”. New England Journal of Medicine23 (2018).
42. Emens LA., et al. “Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study”. Journal of the National Cancer Institute 8 (2011).
43. Wang Q., et al. “Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies”. Cancer Letters 438 (2018).
44. Demaria S and Formenti SC. “Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking”. Journal for ImmunoTherapy of Cancer 4 (2016).
45. Sharabi AB., et al. “Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy”. The Lancet Oncology 16 (2015).
46. Kang J., et al. “Current clinical trials testing the combination of immunotherapy with radiotherapy”. The Journal for ImmunoTherapy of Cancer 1 (2016).
47. Deng L., et al. “Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice”. Journal of Clinical Investigation2 (2014).
48. Bertrand A., et al. “Immune related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis”. BMC Medicine 1 (2015).
49. Ferris RL., et al. “Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck”. New England Journal of Medicine 19 (2016).

Citation

Citation: Azizah Fahad Bin Mubayrik., et al. “A Concise Review of Immune Checkpoint Inhibitors Immunotherapy for Head and Neck Cancer".Acta Scientific Dental Sciences 8.1 (2024): 58-62.

Copyright

Copyright: © 2024 Azizah Fahad Bin Mubayrik., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.